Intensive care, Antibiotics, Pharmacodynamics, Pharmacokinetics
Conditions
Interventions
Assigned interventions in the active TDM group: dosage of beta-lactam and fluoroquinolone antibiotics will be adjusted according to serum concentrations. In the non-TDM (control) group samples of seru
Sponsors
Erasmus MC
Eligibility
Inclusion criteria
Inclusion criteria: - ≥18 years of age - Receiving intravenous antibiotic therapy of the target drugs - Treatment should be aimed for at least 2 days.
Exclusion criteria
Exclusion criteria: - Pregnancy - Patient already enrolled in this trial - Antibiotic cessation before sampling - Medium care and burn wound patients admitted to the ICU - Patients receiving cefotaxime as prophylaxis only within the context of Selective Digestive tract Decontamination (SDD)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacodynamic target attainment: - Beta-lactam: %ƒT>MIC(ECOFF) (including % of patients with 100%ƒT>MIC(ECOFF) in both groups). - Fluoroquinolone: ƒAUC/MIC(ECOFF) (including % of patients with ƒAUC/MIC(ECOFF)≥100 in both groups) | — |
Secondary
| Measure | Time frame |
|---|---|
| To determent if active TDM results in improved clinical outcome, increased cost-effectiveness, better quality of life and less post-ICU syndrome. - Clinical outcomes are 28-day mortality, SOFA (sequential organ failure assessment score, use of other antibiotics, readmittance and procalcitonin decrease. - Cost-effectiveness will be determined directly (costs of stay at ICU, including treatment costs) and using appropriate health – economic analysis. | — |
Contacts
Public ContactA Abdulla
Erasmus Medical Centre - Department of Hospital Pharmacy
Outcome results
None listed